University of Kentucky College of Medcine Bowling Green, KY
Steven Edds, DO1, Rebecca Shadowen, MD2; 1University of Kentucky College of Medcine, Bowling Green, KY; 2Med Center Health, Bowling Green, KY
Introduction: Clostridium difficile infection (CDI) results in approximately a half a million cases and 15,000 deaths annually in the United States. Relapse rates vary between 20-50% and account for frequent readmissions and morbidity. Application of treatment modalities for relapsing cases resulting in complete resolution is reported here. Methods: An observational analytical cohort study was done from June 2014-December 2018 by offering options to patients for treatment of their CDI relapse. Each chose between Fecal Microbiota Transplantation (FMT; N=52), Vancomycin po 6-week taper (VTa; N=4), or Vancomycin 125 mg po daily 6-month suppression (VSu; N=18). The FMT was given either as a liquid NG instillation (FMT-L) twice 12-24 hours apart (N=47) or 20 capsules (FMT-C) given over 90 minutes (N=5). Patients were followed for at least 8 weeks after treatment with readmissions tracked for 6 months in all cases. Fisher’s Exact Test was used for statistical significance. Results: No patient was readmitted to the hospital for CDI associated problems during the term of this study. More men choose po Vancomycin with more women choosing FMT (VTa/VSu Female 38%: Male 62% and FMT Female 80%: Male 20%; p< 0.01). Overall initial response rate was 90%. Resolution of CDI was highest among the FMT-L (95.7 %; N=45/47; p= 1) and the VSu (94%; N-17/18; p= 1). The VTa group had 75% resolution (N=3/4; nsd). The FMT-C arm showed a 40% success rate (N=2/5; nsd). Treatment failures (N=7) chose re-treatment with 6 cases repeating VTa having one relapse responding to FMT-L. One relapse in the VSu group responded to a 6 months daily Vancomycin suppressive course. The only statistically significant difference was in male to female ratios. Cost of therapy was highest for FMT-L $2326, FMT-C $1870, VSu $965, and VTa $700 average per course. Discussion: This report integrates options in treatment that follows the relapsing CDI patient to complete resolution. This eliminated hospital readmission and further morbidity. Allowing the patient freedom of treatment option was well received. Of the treatment arms, FMT-L and VSu were equivalent in outcomes, followed by VTa and FMT-C. FMT-L as 2 instillations provides higher response rates than previously reported. This was a small sample size, however primary study endpoints of no hospitalizations and complete resolution were attained.
Disclosures: Steven Edds indicated no relevant financial relationships. Rebecca Shadowen indicated no relevant financial relationships.